Oxford Asset Management’s Aerie Pharmaceuticals AERI Stock Holding History

Oxford Asset Management’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-33,928	Closed	-$1M	–	2019
2019 Q2	$1M	Buy	+33,928	New	+$1.31M	0.02%	974
2018 Q4	–	Sell	-8,329	Closed	-$512K	–	2200
2018 Q3	$512K	Buy	8,329 +28	+0.3%	+$1.8K	0.01%	1302
2018 Q2	$562K	Buy	+8,301	New	+$464K	0.01%	1302
2018 Q1	–	Sell	-11,265	Closed	-$679K	–	1966
2017 Q4	$679K	Sell	11,265 -6,461	-36%	-$392K	0.01%	1090
2017 Q3	$859K	Buy	+17,726	New	+$967K	0.02%	1002
2016 Q1	–	Sell	-75,169	Closed	-$1.84M	–	932
2015 Q4	$1.84M	Buy	+75,169	New	+$1.75M	0.04%	418

Other funds holding AERI

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Oxford Asset Management's AERI Position: Q3 2019 in Review

Oxford Asset Management sold out of Aerie Pharmaceuticals (AERI) in Q3 2019, closing a stake of 33,928 shares — an estimated $1M sold.

Oxford Asset Management first reported a position in AERI in Q4 2015 and held it in 6 quarters. The position peaked at $1.84M in Q4 2015. 167 funds tracked by Wall St. Rank hold AERI as of Q3 2019.

Oxford Asset Management reported no remaining Aerie Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Oxford Asset Management sold 33,928 Aerie Pharmaceuticals shares in Q3 2019, an estimated $1M.
Oxford Asset Management first reported a position in Aerie Pharmaceuticals in Q4 2015 and held it in 6 quarters.
Oxford Asset Management's Aerie Pharmaceuticals position peaked at $1.84M in Q4 2015.
167 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q3 2019.

Based on Oxford Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.